Article
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Breast cancer research : BCR - 27 Jan 2014
Beelen Karin, Opdam Mark, Severson Tesa M, Koornstra Rutger H T, Vincent Andrew D, Wesseling Jelle, Muris Jettie J, Berns Els M J J, Vermorken Jan B, van Diest Paul J, Linn Sabine C
Abstract excerpt
INTRODUCTION: Inhibitors of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway can overcome endocrine resistance in estrogen receptor (ER) α-positive breast cancer, but companion diagnostics indicating PI3K/AKT/mTOR activation and consequently endocrine resistance are lacking. PIK3CA mutations frequently occur in ERα-positive breast cancer and result in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.